Literature DB >> 12573598

Pharmacokinetics and PK-PD modelling of danofloxacin in camel serum and tissue cage fluids.

F Shojaee Aliabadi1, Badrelin H Ali, M F Landoni, P Lees.   

Abstract

The pharmacokinetics and pharmacodynamics of danofloxacin were studied in the camel in a two period cross-over study. After intravenous (i.v.) administration at a dose rate of 1.25 mg/kg, the pharmacokinetics of danofloxacin indicated a high volume of distribution (V(d(area))=3.43 L/kg), relatively rapid clearance (0.44 L/kg/h) and half-life of 5.37 h. After intramuscular (i.m.) dosing absorption was complete (F=114.5) and rapid (T((1/2)abs)=0.12 h) and terminal half-life was 5.71 h. Danofloxacin penetrated fairly slowly into both inflamed (exudate) and non-inflamed (transudate) tissue cage fluids and was cleared slowly from these fluids, elimination half-life being at least twice that for serum for both exudate and transudate after both i.v. and i.m. dosing. The antibacterial actions of danofloxacin against the camel pathogen Escherichia coli 0157-H7 were determined by measurement of minimum inhibitory concentration (MIC) in vitro (single measurement) and ex vivo measurements of bacterial count at nine times between one and 48 h after i.m. dosing in each of the fluids, serum, exudate, and transudate. Using in vitro MIC data and in vivo pharmacokinetic parameters, the surrogate markers of antimicrobial activity, C(max)/MIC, AUC/MIC and T>MIC, were determined for all three fluids. The ex vivo serum AUC(24 h)/MIC data were integrated with reduction in bacterial count to provide values producing a bacteriostatic action (no change in bacterial count), inhibition of bacterial count by 50%, reduction in bacterial count by 99.9% (bactericidal action) and elimination of bacteria. Mean AUC(24h)/MIC values were 17.20, 20.07, 21.24, and 68.37 h, respectively. To describe the latter, the introduction of a new term to supplement MIC and minimum bactericidal concentration (MBC) is proposed, namely minimum elimination concentration (MEC). A novel means of designing antimicrobial drug dosage schedules for evaluation in clinical trials is proposed, using ex vivo AUC(24h)/MIC values for bactericidal activity and elimination of bacteria together with MIC(90) data for camel pathogens.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12573598     DOI: 10.1016/s1090-0233(02)00258-7

Source DB:  PubMed          Journal:  Vet J        ISSN: 1090-0233            Impact factor:   2.688


  21 in total

1.  Integration of pharmacokinetic and pharmacodynamic indices of marbofloxacin in turkeys.

Authors:  Aneliya Milanova Haritova; Nikolina Velizarova Rusenova; Parvan Rusenov Parvanov; Lubomir Dimitrov Lashev; Johanna Fink-Gremmels
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

2.  Pharmacokinetic-pharmacodynamic modelling of danofloxacin in turkeys.

Authors:  A M Haritova; N V Rusenova; P R Parvanov; L D Lashev; J Fink-Gremmels
Journal:  Vet Res Commun       Date:  2006-10       Impact factor: 2.459

3.  Preparation and evaluation of danofloxacin mesylate microspheres and its pharmacokinetics in pigs.

Authors:  Chunmei Wang; Diyun Ai; Cuilan Chen; Heng Lin; Jing Li; Hongchun Shen; Weixue Yi; Yuanhua Qi; Haigang Wu; Jiyue Cao
Journal:  Vet Res Commun       Date:  2009-09-23       Impact factor: 2.459

4.  Integration of pharmacokinetic and pharmacodynamic indices of orbifloxacin in beagle dogs after a single intravenous and intramuscular administration.

Authors:  Elias Gebru; Joong-Su Lee; Zhi-Qiang Chang; Mi-Hyun Hwang; Henrique Cheng; Seung-Chun Park
Journal:  Antimicrob Agents Chemother       Date:  2009-04-27       Impact factor: 5.191

5.  Comparative plasma pharmacokinetics and tolerance of florfenicol following intramuscular and intravenous administration to camels, sheep and goats.

Authors:  B H Ali; A A Al-Qarawi; M Hashaad
Journal:  Vet Res Commun       Date:  2003-09       Impact factor: 2.459

6.  Pharmacokinetic and Pharmacodynamic Integration and Modeling of Enrofloxacin in Swine for Escherichia coli.

Authors:  Jianyi Wang; Haihong Hao; Lingli Huang; Zhenli Liu; Dongmei Chen; Zonghui Yuan
Journal:  Front Microbiol       Date:  2016-02-02       Impact factor: 5.640

7.  Disposition kinetics and dosage regimen of levofloxacin on concomitant administration with paracetamol in crossbred calves.

Authors:  Vinod K Dumka
Journal:  J Vet Sci       Date:  2007-12       Impact factor: 1.672

8.  Antimicrobial breakpoint estimation accounting for variability in pharmacokinetics.

Authors:  Goue Denis Gohore Bi; Jun Li; Fahima Nekka
Journal:  Theor Biol Med Model       Date:  2009-06-26       Impact factor: 2.432

9.  Pharmacokinetic/Pharmacodynamic Correlation of Cefquinome Against Experimental Catheter-Associated Biofilm Infection Due to Staphylococcus aureus.

Authors:  Yu-Feng Zhou; Wei Shi; Yang Yu; Meng-Ting Tao; Yan Q Xiong; Jian Sun; Ya-Hong Liu
Journal:  Front Microbiol       Date:  2016-01-07       Impact factor: 5.640

10.  PK-PD Integration Modeling and Cutoff Value of Florfenicol against Streptococcus suis in Pigs.

Authors:  Zhixin Lei; Qianying Liu; Shuaike Yang; Bing Yang; Haseeb Khaliq; Kun Li; Saeed Ahmed; Abdul Sajid; Bingzhou Zhang; Pin Chen; Yinsheng Qiu; Jiyue Cao; Qigai He
Journal:  Front Pharmacol       Date:  2018-01-17       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.